Trial Profile
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 08 Feb 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 23 Aug 2018 Status changed from active, no longer recruiting to completed.
- 21 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.